• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

1. What Delstrigo is and what it is used for
2. What you need to know before you take Delstrigo
3. How to take Delstrigo
4. Possible side effects
5. How to store Delstrigo
6. Contents of the pack and other information

Delstrigo is used to treat HIV (‘human immunodeficiency virus’) infection. It belongs to a group of medicines called ‘antiretroviral medicines’.

Delstrigo contains the active substances:

• Doravirine - a non-nucleoside reverse transcriptase inhibitor (NNRTI)
• Lamivudine - a nucleoside analogue reverse transcriptase inhibitor (NRTI)
• Tenofovir disoproxil - a nucleoside analogue reverse transcriptase inhibitor (NRTI)

Delstrigo is used to treat HIV infection in adults and adolescents aged 12 years and older weighing at least 35 kg. HIV is the virus that causes AIDS (‘acquired immune deficiency syndrome’). You should not take Delstrigo if your doctor has told you that the virus causing your infection is resistant to any of the medicines in Delstrigo.

Delstrigo works by preventing HIV from making more viruses in your body. This will help by:

• reducing the amount of HIV in your blood (this is called your ‘viral load’)
• increasing the number of white blood cells called ‘CD4+ T’. This can make your immune system stronger. This may reduce your risk of early death or catching infections because your immune system is weak.

• if you are allergic to doravirine, lamivudine or tenofovir disoproxil or any of the other ingredients of this medicine listed in section 6.
• if you are taking any of the following medicines:
  • carbamazepine, oxcarbazepine, phenobarbital, phenytoin (medicines for seizure)
  • rifampicin, rifapentine (medicines for tuberculosis)
  • St. John’s wort (Hypericum perforatum, a herbal remedy used for depression and anxiety) or products that contain it
  • mitotane (a medicine to treat cancer)
  • enzalutamide (a medicine to treat prostate cancer)
  • lumacaftor (a medicine to treat cystic fibrosis)

Do not take Delstrigo if the above applies to you. If you are not sure, talk to your doctor, pharmacist, or nurse before taking Delstrigo. See also the list in section “Other Medicines and Delstrigo”.

Talk to your doctor, pharmacist, or nurse before taking Delstrigo.

If you have both HIV and hepatitis B virus infections, your hepatitis B may get worse if you stop taking Delstrigo. You may require blood tests for several months after stopping treatment. Discuss your hepatitis B therapy with your doctor.

This can happen in some people who take Delstrigo. Your doctor will do blood tests to check your kidney function before and during treatment with Delstrigo.

This can happen in some people who take Delstrigo. Bone problems include bone pain, and bone softening or thinning (which may lead to fractures). Joint or muscle pain or muscle weakness may also occur. Your doctor may need to do additional tests to check your bones.

This can happen when you start taking any HIV medicine, including Delstrigo. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your doctor right away if you start having any new symptoms after starting your HIV medicine.

Autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.

Do not give this medicine to children aged less than 12 years or weighing less than 35 kg. The use of Delstrigo in children aged less than 12 years or weighing less than 35 kg has not yet been studied.

Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines. This is because other medicines may affect how Delstrigo works, and Delstrigo might affect the way some other medicines work.

There are some medicines you must not take with Delstrigo. See list under “Do not take Delstrigo” section.

Talk to your doctor before taking the following medicines with Delstrigo as your doctor may need to change the dose of your medicines:

• bosentan (a medicine to treat lung disease)
• dabrafenib (a medicine to treat skin cancer)
• lesinurad (a medicine to treat gout)
• modafinil (a medicine to treat excessive sleepiness)
• nafcillin (a medicine to treat some bacterial infections)
• rifabutin (a medicine to treat some bacterial infections such as tuberculosis)
• telotristat ethyl (a medicine to treat diarrhea in people with carcinoid syndrome)
• thioridazine (a medicine to treat psychiatric conditions such as schizophrenia)

If your doctor decides you should take these medicines with Delstrigo, your doctor will prescribe a 100 mg tablet of doravirine to be taken daily, approximately 12 hours after your dose of Delstrigo.

Your doctor may check your blood levels or monitor for side effects if you take the following medicines with Delstrigo:

• ledipasvir/sofosbuvir (medicines used to treat hepatitis C infection)
• sirolimus (a medicine used to control your body’s immune response after a transplant)
• sofosbuvir/velpatasvir (medicines used to treat hepatitis C infection)
• tacrolimus (a medicine used to control your body’s immune response after a transplant)
• medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, talk to your doctor about the risks and benefits of taking Delstrigo. It is preferable to avoid the use of Delstrigo during pregnancy. This is because it has not been studied in pregnancy and it is not known if Delstrigo will harm your baby while you are pregnant.

Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk.

If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.

Use with caution when driving, riding a bicycle, or operating machines if you feel tired, dizzy, or sleepy after taking this medicine

If you have been told by your doctor that you have an intolerance to lactose, talk to your doctor before taking this medicine.

The recommended dose is 1 tablet once a day. If you take certain medicines your doctor may need to change the amount of doravirine you take. See “Other medicines and Delstrigo” section for a list of medicines.

• Swallow the tablet whole (do not crush or chew).
• This medicine can be taken with food or between meals.

Do not take more than the recommended dose. If you accidentally take more, contact your doctor.

• It is important that you do not miss or skip doses of Delstrigo.
• If you forget a dose, take it as soon as you remember. But if your next dose is due within 12 hours, skip the dose you missed and take the next one at the usual time. Then continue your treatment as before.
• Do not take two doses of Delstrigo at the same time to make up for a missed dose.
• If you are not sure what to do, call your doctor or pharmacist.

Do not run out of Delstrigo. Refill your prescription or talk to your doctor before your Delstrigo is all gone.

If you stop taking Delstrigo, your doctor will need to check your health often and do blood tests regularly for several months to check your HIV infection. If you have HIV infection and hepatitis B infection, it is especially important not to stop your Delstrigo treatment without talking to your doctor first. Some patients have had blood tests or symptoms indicating that their hepatitis has worsened after stopping lamivudine or tenofovir disoproxil (two of the three active substances of Delstrigo). If Delstrigo is stopped your doctor may recommend that you resume hepatitis B treatment. You may need blood tests to check how your liver is working for 4 months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

• The active substances are 100 mg of doravirine, 300 mg of lamivudine and 245 mg of tenofovir disoproxil (as fumarate)
• The other ingredients are croscarmellose sodium E468; hypromellose acetate succinate; magnesium stearate E470b; microcrystalline cellulose E460; silica, colloidal anhydrous E551; sodium stearyl fumarate. The tablets are film-coated with a coating material containing the following ingredients: carnauba wax E903, hypromellose E464; iron oxide yellow E172; lactose monohydrate; titanium dioxide E171; and triacetin E1518.

Delstrigo is available as a yellow, oval-shaped, film-coated tablet, and is debossed with the corporate logo and 776 on one side and plain on the other side.

The following pack sizes are available:

• 1 bottle with 30 film-coated tablets
• 90 film-coated tablets (3 bottles of 30 film-coated tablets)

Not all pack sizes may be available in your country.

Marketing Authorisation Holder:

Manufacturer:

Other sources of information

For any information about this medicine, please contact: